Results 31 to 40 of about 4,843 (156)
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Cardiovascular Diabetology, 2019 Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and ...Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic, Lawrence A. Leiter +11 moredoaj +1 more sourceEfficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) [PDF]
, 2017 The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C).Mahfouz El Shahawy, Guillaume Lecorps, Blom, Dirk J, Dirk J. Blom, Cannon, Christopher P, Colhoun, Helen M, Umesh Chaudhari, Bertrand Cariou, Chaudhari, Umesh, James M. McKenney, El Shahawy, Mahfouz, Christopher P. Cannon, Pordy, Robert, Helen M. Colhoun, Cariou, Bertrand, Robert Pordy, Lecorps, Guillaume, McKenney, James M +17 morecore +1 more sourceEffect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program) [PDF]
, 2017 Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are limited.Sasiela, William J., Gaudet, Daniel, Robinson, Jennifer G., Minini, Pascal, Raal, Frederick J., Louie, Michael J., Edelberg, Jay, Watts, Gerald F. +7 morecore +1 more sourceAlirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial [PDF]
, 2018 Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute ...Mehta, R.H., Poulsen, S.H., Liberopoulos, E., Matas Pericas, Laia, Hanotin, Corinne, Giordano, J.A., Zobouyan, Isabelle, Muller, C., Hagström, Emil, Sasiela, W.J., Pereira, S.B., Mackinnon, I.J., Colombo, H.R., DeVore, A.D., Nieminen, M.S., Aylward, P.E., Moriarty, P.M., Vallejos, J.A., Endsley, P., Vulic, D., Schmidberg, J.M., Eapen, Z., Arstall, M.A., Harrington, R.A., Clifton, S., Sujjavanich, D., Moryusef, Angèle, Waites, J.H., Patel, C.B., Dran, R.D., Schwartz, G.G., Raffel, O., Bordonava, A.P., Shaw, J., Murin, J., Eliaschewitz, F.G., Steg, P. Gabriel, Pimentel, P., Valgimigli, M., Silva, H.A. de, Vrolix, M.C.M., Caccavo, A., Zeiher, Andreas Michael, Caruso, O.C., Mahaffey, Kenneth, Hrabar, A.D., Jukema, J. Wouter, Horowitz, J., Goodman, Shaun G., Schiavi, L.B., Jure, H.O., White, Harvey D., Vidotti, M.H., Fazlibegovic, E., Alings, M., Dilic, M., Labarta, M.H.B., Sousa, L., Kelsey, S.F., Kolls, B.J., Hoffer, E., Hagstrom, E., Collins, N., Bittner, Vera A., Edelberg, J.M., Chaitman, B., Mahaffey, Kenneth W., Diepen, S.F.P. van, Zapata, G., Sader, M., Mathews, R., Pojskic, B., Lopez-Jaramillo, P., Cartasegna, L.R., Guzman, P.N., Sy, R.G., Harrison, R.W., Carnero, G.S., Allende, J.C.M., Meloni, C., Schwartz, Gregory G., Roe, Matthew T., Eppinger, A., Novoa, F., Hoppe, U., Chua, T., Codutti, O.R., Mentz, R.J., Giorgeto, F.E., Lopez, G.A.R., Claeys, M., Bhatt, Deepak L., Fras, Z., Patocchi, C.A., White, Harvey, Aroney, C., Silva, R.P., Edelberg, Jay M., Terzic, I., Kiss, Robert Gabor, Morais, J., Steg, Ph. Gabriel, Nicolau, J.C., Michalaros, Y.L., Rosenson, R., Costamagna, O., Gislason, Gunnar, Brennan, J.M., Yan, A.T.K., Faes, D., Lopes, R.D., Zeiher, Andreas M., Carroll, P.A., Wolf, L. de, Davidsen, Flemming, Tse, H.F., Alexander, J.H., Toma, M., Goodman, S.G., Leonardi, S., Gotcheva, N.N., Puymirat, E., Llois, S., Zweiker, R., Chumburidze, V., Mahaffey, K.W., Tamby, J.F., Sinnaeve, P., Armaganijan, L., Brasca, D.F.G., Lecorps, Guillaume, Flores, R.E.O., Cequier Fillat, Angel R., Lopez, R., Jones, W.S., Ducrocq, G., Roe, M.T., Moreira, H.G., Kim, H.S., Striekwold, H., Lehman, S.J., Steg, G., Tunon, J., Bhatt, D.L., Vico, M.L., Neuenschwander, F., Harrington, Robert A., Universitat Autònoma de Barcelona, Dick, R., Goronja, B., Kimura, T., Duran, R.O.G., Szarek, M., Kormann, A., Huber, K., Weidinger, F., Kong, D.F., Erglis, A., Leggewie, Stefan, Convens, C., Sijbrands, E.J.G., Chiang, C.E., Kiss, R.G., Nani, S., Luquez, H.A., Pirenne, B., Duda, N., Pecin, I., Viigimaa, M., Berger, R., Gil Extremera, Blas, Deloatch, S., Marx, N., Novaretto, L.P., Bruguera Cortada, Jordi, Andersen, Dorthe, Dujardin, K., Danchin, N., Kim, S.H., Tricoci, P., Hanotin, C., Vervoort, G., Hess, C.N., Vilamajo, O.A.G., Muslibegovic, A., Stringfellow, K., Ristic, A.D., Zirlik, Andreas, Hlatky, M.A., Kedev, S., Hii, C.L.S., Rech, R., Berli, M.A., Marcus, J., Starmer, G., Barbato, E., Jukema, J.W., Durak-Nalbantic, A., Flores, R.M.C., Santos, M.O.N. de, Caime, G.D., Garrahy, P.J., Szarek, Michael, Guneri, S., Olsson, A.G., Lecorps, G., Hominal, M.A., Moryusef, A., Alvarisqueta, A.F., Lorenzatti, A.J., Liberman, A., Cools, F., Budaj, A., Waisman, G.D., Valdovinos, P.C.M., Rouleau, J.L., Maia, L.N., Sritara, P., Laucevicius, A., Perkins, L., Saavedra, S.S., Parkhomenko, A., Karpov, Y., Bagai, A., Duronto, E.A., Roberts-Thomson, P., Blumberg, E.D.S., Pordy, R., Shah, B.R., García-Dorado, David, Reiner, Željko, Dombrowski, K., Leone, A., Steg, P.G., Steg, Ph Gabriel, Bittner, V.A., Povsic, T.J., Zahger, D., Coca Payeras, Antonio, Yusoff, K., Hermans, K., Dalby, A.J., Trotter, C., Clemmensen, Peter, Larsen, John, Dickey, S., Lillis, L., Prieto, J.C., Abrantes, J.A.M., Tricoci, Pierluigi, Guerrero, R.A.A., Peršić, Viktor, Bono, J.O.E., Sassone, S.A., Bittner, Vera, Pordy, Robert, Simoons, M.L., Bahit, M.C., Hagström, Emil,, Halvorsen, S., Xavier, D., Luciardi, H.L., Zaidman, C.J., Salomone, R., Ostadal, P., Zeiher, A.M., Jukema, J.Wouter, Giuliano, M.E., Diaz, R., Drexel, H., Knowles, J.W., Montana, O.R., Roosen, J., Alings, Marco, Maron, D.J., Bodanese, L.C., Tomulić, Vjekoslav, Wilson, M.D., Alexander, K., Ray, K.K., Amuchastegui, M., Colquhoun, D., Castadot, M., Sherwood, M.W., Rossi, P.R.F., Yong, H., Kalil, R., Gusi Tragant, Gabriel, Diaz, Rafael, Xavier, Denis, Bhatt, Deepak L, Lima, A.E.A. de, Barakovic, F., Steg, Gabriel, Jordan, J.D., Garrido, M., Paterlini, G.A., Reiner, Z., Dorobantu, M., Leaes, P.E, Reis, G., Wollaert, B., Videbaek, Lars, Rogers, J.F., Cestari, H.G., Soggia, A.P., Kimura, Takeshi, Beauloye, C., Chiang, Chern-En, White, H.D., Soward, A., Coverdale, S.G.M., Midzic, Z., Cerqueira, M.J.A.G. +313 morecore +2 more sourcesA retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients [PDF]
, 2020 BACKGROUND: The previously published ODYSSEY ESCAPE trial demonstrated a significant reduction in the use of lipoprotein apheresis for heterozygous familial hypercholesterolemia (HeFH) patients when placed on alirocumab 150 mg every 2 weeks.Wooten, Michael, Hemphill, Linda, Dunbar, Richard L, Wilson, Gerald, Dacus, Kelley, Goldberg, Anne C, Moriarty, Patrick M, Babirak, Stephan P, Minchew, Heather, Dutton, Julie-Ann, Iydroose, Mohamed +10 morecore +1 more sourceA Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice
Drugs - Real World Outcomes, 2019 Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein Tim Reynolds, Peter Carey, Jacob George, Gerasimos Konidaris, Deepa Narayanan, Sudarshan Ramachandran, Luke Saunders, Adie Viljoen, Gordon Ferns +8 moredoaj +1 more source
